You are here
In a new study that included more than 76,000 patients, researchers from Intermountain Healthcare in Salt Lake City found that the chance of developing dementia increases when the start of anticoagulation treatment is delayed for atrial fibrillation (AFib).
A new study from Cincinnati’s Children’s Hospital has found that the use of a wearable cardioverter defibrillator (WCD) is safe and effective for treating ventricular arrhythmias in pediatric patients at risk from sudden cardiac death.
Apple devices just keep getting smarter. New research presented at this year’s Heart Rhythm Society (HRS) conference in Chicago showed that when paired with an artificial intelligence-based algorithm, the watch can detect atrial fibrillation (AFib).
Though physicians typically use adenosine, calcium channel blockers or beta-blockers in patients suffering from paroxysmal supraventricular tachycardia (PSVT), new research has given evidence that a simple, self-use nasal spray could be effective, too.
Dublin-based Medtronic revealed encouraging results from a study completed on its Micra Transcatheter Pacing System (TPS), which showed a 99.6 percent implant success rate and low chances of major complications occurring.
Just last week, Lake Oswego, Oregon-based Biotronik announced that two of its new products, the SentusProMRI and its MultiPole Pacing technology, were approved by the U.S. Food and Drug Administration (FDA). This week at the annual Heart Rhythm Society conference in Chicago, the company showed off the new devices.
While atrial fibrillation (AFib) and heart disease continue to plague patients globally, some cardiologists have made it their mission to help underserved communities in foreign countries as they look for ways to use their specialties for good.